Tsutsumi, Ryouhei http://orcid.org/0000-0002-1704-0362
Ueberheide, Beatrix
Liang, Feng-Xia http://orcid.org/0000-0003-0037-4590
Neel, Benjamin G.
Sakai, Ryuichi http://orcid.org/0000-0001-6833-1103
Saito, Yoshiro http://orcid.org/0000-0002-0559-5889
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (18H06120, 20K06633, 20H00488)
Takeda Science Foundation
Kato Memorial Bioscience Foundation
U.S. Department of Health & Human Services | National Institutes of Health (1S10OD010582-01A1, R01 CA49152)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA016087, P30CA016087)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 2 August 2023
Accepted: 15 March 2024
First Online: 2 April 2024
Competing interests
: B.G.N. is co-founder and received equity and consulting fees from Northern Biologics, Navire Pharma, Lighthorse Therapeutics and Aethon Therapeutics. He also is on the Scientific Advisory Boards of Arvinas and Recursion and received consulting fees and equity from each. His spouse own shares in Moderna. The remaining authors declare no competing interests.